Doctor Randy Blakely explains that all neurotransmitters have transporters supporting their activity, which are typically involved in assisting and modulating. Genetic changes in transporters can lead to psychiatric problems.
All neurotransmitters â€“ small molecule neurotransmitters â€“ have transporters supporting their activity. So in the big scheme of things, yes, transporter genetic changes can be as important as changes in receptors or ion channels. Many of these transporters, though, are assisting and modulating neurotransmitter action. They are not necessarily essential for neurotransmitter action, so changes â€“ genetic changes â€“ in them often donâ€™t result in a person, letâ€™s say, not being born at all, or having a very severe mental retardation, but they will have behavioral difficulties and behavioral syndromes that are common to psychiatry. Genetic variation in these molecules is part of the larger network of genetic variation that can influence the signaling of these molecules â€“ these neurotransmitters. So, youâ€™ll find that there are going to be rare individuals, families, small numbers of families, where there are these mutations in these transporter proteins.They may not be that common. They may, in fact our evidence suggests, that for many neuropsychiatric disorders, these transporters are intact, there is nothing different about the protein that is made. But what we learn from the rare families that do have these mutations is how important control over the neurotransmitter is for appropriate neural function. We take our leads from that to look more broadly in the network of, letâ€™s say, transporter regulatory proteins.
neurotransmitter, small molecule, transporter, regulatory, genetic variation, neuropsychiatric, ion channels, receptors, randy, blakely
Professor Randy Blakely explains that biogenic amines include transmitters like serotonin, dopamine, and norepinephrine. Transporters assist these amines at synapses.
Doctor Randy Blakely introduces biogenic amines transporters, which remove biogenic amines such as serotonin, dopamine, and norepinephrine from extracellular space, keeping the path clear for the next pulse of neurotransmitter.
Professor Randy Blakely discusses the impact of gene variation (polymorphisms) on transporter proteins. Impact can be very subtle and is linked to regulatory processes.
Communication in brain cells is guided by interactions between genes and biochemicals at the synapse. These interactions can lead to the formation of new synapses.
Doctor Randy Blakely speculates that the traditional view that drugs though to increase serotonin and dopamine levels in the brain may work by preventing a backward-running state.
Doctor Randy Blakely discusses the association between the dopamine transporter and ADHD, and discusses a possible relationship with bipolar disorder and schizophrenia.
Doctor Randy Blakely discusses the role of the dopamine and serotonin systems in a number of clinical disorders.
Cognitive information is encoded in patterns of nervous activity and decoded by molecular listening devices at the synapse. Professor Seth Grant explains how different patterns of neural firing are critical to cognition.
Doctor Randy Blakely interprets the high success rate in treating ADHD with drugs as evidence of a common mechanism underlying the disorder that these drugs are attacking
Doctor Randy Blakely describes an intriguing hypothesis for why amphetamine may be effective in treating some individuals with ADHD.